- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Rehospitalization Reductions After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer
Daxor (NYSE:DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by …
Daxor (NYSE:DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by blood volume measurement with the BVA-100 blood volume analyzer, compared to propensity-matched controls.
As quoted in the press release:
“This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes. Heart failure represents one of the largest areas of healthcare spending and one of the most significant treatment challenges for approximately 6 million US patients, which is expected to double as the population ages,” commented Michael Feldschuh, CEO of Daxor. “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”
Treatment guided by the BVA-100 blood volume analyzer resulted in a statistically significant decrease in rehospitalization (12.2 percent vs. 27.7 percent, p<0.001), 30-day mortality (2.0 percent vs. 11.1 percent, p<0.001) and 365-day mortality (4.9 percent vs. 35.5. percent, p<0.001), compared to a propensity score control. Further, an analysis of 30-day readmission by diagnosis showed fewer heart failure readmissions (6.1 percent vs. 20.2 percent, p<0.001) and fewer cardiac non-heart failure admissions (1.6 percent vs. 3.9 percent, p<0.001).
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.